← Back to Directory List

Suzanne Ostrand-Rosenberg

Suzanne Ostrand-Rosenberg

Prof. Biology, Robert+Jane Meyerhoff Chair

Biological Sciences

Biological Sciences Bldg 221

Education

Ph D California Institute of Technology 1975

AB Barnard College, Columbia University 1970

About

I have more than 37 years of experience as the PI of a laboratory studying the immune system’s response to malignancies. Throughout this period my lab’s long-term goal has been to manipulate an individual's immune response to reject cancer cells. In the 1990’s we were instrumental in demonstrating that CD4+ T helper lymphocytes are essential for immune-mediated tumor rejection. Recently, we were among the first labs to appreciate that myeloid-derived suppressor cells (MDSC) are highly immune suppressive cells present in virtually all cancer patients, and are a significant obstacle to active cancer immunotherapies. Our work demonstrating that MDSC are induced by a variety of pro-inflammatory mediators was described in a Science Magazine “News Focus” article and is the basis for the concept that chronic inflammation increases cancer risk and cancer progression by inducing MDSC which inhibit anti-tumor immunity. Our lab was also the first to demonstrate that macrophages, the other major pro-tumor myeloid cell population that infiltrates solid tumors, undergo cross-talk with MDSC which enhances the pro-tumor activity of both cell populations. Studies to date have identified a variety of physiological conditions and molecules that drive the accumulation and suppressive potency of MDSC and macrophages. However, neutralization of these cells has been unsuccessful because of the multiple pro-inflammatory mediators that drive their accumulation and function. Our preliminary studies, which are the basis for this application, demonstrate that the ubiquitously expressed alarmin, HMGB1, and the pro-inflammatory mediator S100A8/A9, are master regulators that activate MDSC by binding to the Receptor for Advanced Glycation Endproducts (RAGE). These observations led us to hypothesize that pro-tumor MDSC and TAMs may be neutralized by targeting RAGE, HMGB1, and S100A8/A9. If our hypothesis is correct, then our studies will provide a global and universal strategy for eliminating the suppressive activity of these myeloid cell populations and provide a more favorable environment for immunotherapy in cancer patients.

Research Interests

Tumor/cancer immunology; tumor-induced immune suppression; cancer vaccine development

Teaching Interests

Immunology Cell Biology Cancer Biology

Selected Classes

  • Spring 2014 BIOL 397 – Ethics and Integrity in Scientific Research

Contracts, Fellowships, Grants, and Sponsored Research

Ostrand-Rosenberg, Suzanne.

Ostrand-Rosenberg, Suzanne (Supporting), Eduardo, Davila (Principal). “Amplifying TCR Responses and Resisting MDSC-mediated Suppression via MyD88 Signaling in T cells,” Grant (Not Funded). Sponsored By: NIH.

Ostrand-Rosenberg, Suzanne (Principal), Catherine, Fenselau (Principal), David, Fushman (Principal). “Ubiquitinated Proteins in Exosomes of Immune Suppressive Myeloid Cells.,” Grant (Funded). Sponsored By: NIH. (Feb 1, 2014 – Jun 30, 2018).

Ostrand-Rosenberg, Suzanne (Principal). “Does G-CSF promote maternal-fetal tolerance by inducing immune suppressive myeloid-derived suppresser cells (MDSC)?,” Cooperative Agreement (Funded). Sponsored By: Nora Therapeutics. (Apr 23, 2014 – Apr 22, 2015).

Ostrand-Rosenberg, Suzanne (Principal). “A novel recombinant molecule that simultaneously inhibits PDL1/PD1-mediated immune suppression and boosts the activation of tumor-reactive T cells.,” Cooperative Agreement (Funded). Sponsored By: MedImmune, Inc.. (Sep 3, 2014 – Jun 2, 2016).

Ostrand-Rosenberg, Suzanne (Co-Principal), Fulton, Amy (Principal). “Targeting the COX-2 Pathway to Reduce Breast Cancer Mortality,” Grant (Funded). Sponsored By: VA (UMB subcontract to UMBC). (Jun 1, 2015 – May 30, 2019).

Ostrand-Rosenberg, Suzanne (Principal), Darryl, Carter (Supporting). “A novel BiTE as an immunotherapy drug for the treatment of cancer,” Grant (Funded). Sponsored By: TEDCO MII program. (Sep 28, 2015 – Jun 28, 2016).

Ostrand-Rosenberg, Suzanne (Supporting). “Mechanisms of trans-cell action of tumor suppressors expressed in myeloid cells,” Grant (Currently Under Review). Sponsored By: NIH. (Sep 1, 2018 –

Intellectual Contributions

Ostrand-Rosenberg, Suzanne. (2018). . 51 68-75 Current Opinion in Immunology.

Geis-Asteggiante, Lucia, Belew, Ashton, Clements, Virginia, Edwards, Nathan, Ostrand-Rosenberg, Suzanne, El-Sayed, Najib, Fenselau, Catherine. (2018). . 17 486-498 American Society of Biological Chemistry: Journal of Proteome Research.

Ostrand-Rosenberg, Suzanne, Fenselau, Catherine. (2018). . 200 422-431 American Association of Immunologists: Journal of Immunology.

Adams, Katherine R., Chauhan, Sitara, Patel, Divya B., Clements, Virginia K., Wang, Yan, Jay, Steven, Edwards, Nathan J., Ostrand-Rosenberg, Suzanne, Fenselau, Catherine. (2018). . 17 315-324 American Society of Biological Chemistry: Journal of Proteome Research.

Horn, Lucas A., Long, Tiha M., Atkinson, Ryan, Clements, Virginia K., Ostrand-Rosenberg, Suzanne. (2018). . 6 59-68 American Association of Cancer Research: Cancer Immunology Research.

Horn, Lucas, Caviattone, Nicholas, Atkinson, Ryan, Woldergerima, Netsanet, Wolfe, Julia, Clements, Virginia, Sinha, Pratima, Poudel, Munanchu, Ostrand-Rosenberg, Suzanne. (2017). CD3xPDL1 bi-specific T cell engager (BiTE) simultaneously activates T cells and kills PDL1+ tumor cells. 8 57964-57980 Oncotarget.

Ostrand-Rosenberg, Suzanne, Sinha, Pratima, Figley, Chas, Long, Ramses, Park, DoHwan, Carter, Darryl, Clements, Virginia K. (2016). Frontline Science: Myeloid-derived suppressor cells (MDSCs) facilitate maternal-fetal tolerance in mice. epub Society of Leukocyte Biology: Journal of Leukocyte Biology.

Ku, Amy, Muhitch, Jason, Powers, Colin, Diehl, Michael, Kim, Minhyung, Fisher, Daniel, Sharda, Anand, Clements, Viginia, O'Loughlin, Kieran, Minderman, Hans, Messmer, Michelle, Ma, Jing, Skitzki, Joseph, Steeber, Douglas, Walcheck, Bruce, Ostrand-Rosenberg, Suzanne, Abrams, Scott I., Evans, Sharon S. (2016). Tumor-induced MDSC act via remote control to inhibit L-selectin-dependent adaptive immunity in lymph nodes. 5 eLIFE.

Ostrand-Rosenberg, Suzanne. (2016). Myeloid-derived suppressor cells.. Encyclopedia of Immunobiology 1. 4 511-525 Oxford: Academic Press Elsevier.

Beury, Daniel W., Carter, Kayla A., Nelson, Cassandra, Sinha, Pratima, Hanson, Erica, Nyandjo, Maeva, Fitzgerald, Phillip J., Majeed, Amry, Wali, Neha, Ostrand-Rosenberg, Suzanne. (2016). Myeloid-Derived Suppressor Cell Survival and Function Are Regulated by the Transcription Factor Nrf2. 196 3470-3478 American Association of Immunologists: Journal of Immunology.

Parker, Katherine H., Horn, Lucas A., Ostrand-Rosenberg, Suzanne. (2016). High-mobility group box protein 1 promotes the survival of myeloid-derived suppressor cells by inducing autophagy. 100 463-470 Society of Leukocyte Biology: Journal of Leukocyte Biology.

Ostrand-Rosenberg, Suzanne. (2016). Tolerance and immune suppression in the tumor microenvironment. 299 23-29 Elsevier: Cellular Immunology.

Parker, Katherine H., Beury, Daniel W., Ostrand-Rosenberg, Suzanne. (2015). Myeloid-derived suppressor cells: critical cells driving immune suppression in the tumor microenvironment. Advances in Cancer Research 128 95-139 Advances in Cancer Research.

Ostrand-Rosenberg, Suzanne, Horn, Lucas A., Alvarez, Juan A. (2015). Novel strategies for inhibiting PD-1 pathway-mediated immune suppression while simultaneously delivering activating signals to tumor-reactive T cells. 64 1287-1293 Springer,: Cancer Immunology, Immunotherapy.

Geis-Asteggiante, Lucia, Dhabaria, Avantika, Edwards, Nathan, Ostrand-Rosenberg, Suzanne, Fenselau, Catherine. (2015). Top-down analysis of low mass proteins in exosomes shed by murine myeloid-derived suppressor cells.. 378 264-269 International Journal of Mass Spectrometry.

Burke, Meghan C., Oei, Maria S., Edwards, Nathan J., Ostrand-Rosenberg, Suzanne, Fenselau, Catherine. (2014). Ubiquitinated proteins in exosomes secreted by myeloid-derived suppressor cells. 13 5965-5972 Journal of Proteome Research.

Ostrand-Rosenberg, Suzanne. (2014). The programmed death-1 immune-suppressive pathway: barrier to antitumor immunity. 193 3835-3841 American Association of Immunologists: The Journal of Immunology.

Beury, Daniel W., Parker, Katherine H., Nyandjo, Maeva M., Sinha, Pratima, Kayla, Carter K., Ostrand-Rosenberg, Suzanne. (2014). Cross-talk among myeloid-derived suppressor cells, macrophages, and tumor cells impacts the inflammatory milieu of solid tumors. 96 1109-1118 Society of Leukocyte Biology: Journal of Leukocyte Biology.

Burke, Meghan, Choksawangkam, Ging, Edwards, Nathan, Ostrand-Rosenberg, Suzanne, Fenselau, Catherine. (2014). . 13 836-843 American Chemical Society: J. Proteome Research.

Ostrand-Rosenberg, Suzanne. (2014). . Tumor-Induced Immune Suppression - Mechanisms and Therapeutic Reversal 185-212 NY, Heidelberg,Dordrecht, London: Springer.

Haile, Samuel, Dalal, Sonia P., Virginia, Clements K., Koji, Tamada, Ostrand-Rosenberg, Suzanne. (2013). . 191 2829-2836 J. of Immunology.

Sinha, Pratima, Ostrand-Rosenberg, Suzanne. (2013). . 62 1663-1673 NY, Heidelberg,Dordrecht, London: Springer.

Ostrand-Rosenberg, Suzanne, Sinha, Pratima. (2013). . Tumor Immunoenvironment NY, Heidelberg,Dordrecht, London: Springer.

Ostrand-Rosenberg, Suzanne. (2013). . 62 1-2 Berlin-Heidelberg: Springer-Verlag.

Ostrand-Rosenberg, Suzanne. . Encyclopedia of Immunology Elsevier.

Binnewies, Mikhail, Roberts, Edward, Kersten, KJelly, Chan, Vincent, Fearon, Douglas, Merad, Miriam, Coussens, Lisa, Gabrilovich, Dmitry, Ostrand-Rosenberg, Suzanne, Hedrick, Catherine, Vonderheide, Robert, Pittet, Mikael, Jain, Rakesh, Zou, Weiping, Howcroft, Kevin, Woodhouse, Elisa, Weinberg, Bob, Krummel, Matthew. Understanding the Tumor Immune Microenvironment (TIME) for effective therapy. springer/Nature: Nature Medicine.

Intellectual Property

Ostrand-Rosenberg, Suzanne. Patent, “Solulble CD80 as a therapeutic to reverse immune suppression in cancer patients,” 13/660,037. Oct 25, 2011 Oct 25, 2012 Dec 5, 2014 Ostrand-Rosenberg, Suzanne, Carter, Darryl. Patent, “Recombinant Bi-specific Polypeptides for Coordinately Activating Tumor-reative T Cells and Neutralizing Immune Suppression,” 62092506 (application number). Dec 16, 2014

Research In Progress

Ostrand-Rosenberg, Suzanne. “Myeloid-derived suppressor cells (MDSC) promote tumor progression and weight gain, but protect against metabolic dysfunction in obese mice,” Scholarly (On-Going). Mar 1, 2015

Presentations

Ostrand-Rosenberg, Suzanne. 1st European Symposium on Myeloid Regulatory Cells in Health and Disease. Lecture. Mye-EUNITER. Essen, Germany. (Nov 1, 2018).

Ostrand-Rosenberg, Suzanne. Infection and Immunity Research Forum (IIRF) Annual conference. Keynote/Plenary Address. IIRF. Western University, London, Ontario Canada. (Oct 11, 2018).

Ostrand-Rosenberg, Suzanne. Progress in Vaccination Against Cancer 18. Lecture. PIVAC 18. Oslo, Norway. (Oct 3, 2018).

Ostrand-Rosenberg, Suzanne. Frontiers in Molecular Oncology International Conference. Keynote/Plenary Address. "Myeloid-derived suppressor cells: Potent immune suppressors in the tumor microenvironment," Universidade Estadual Paulista. Sao Paulo, Brazil. (Jun 9, 2018).

Ostrand-Rosenberg, Suzanne (Author & Presenter). American Association of Immunologists Annual conference. Lecture. "Writing Scientific Manuscripts and Responding to Reviewers," American Association of Immunologists. Austin, TX. (May 6, 2018).

Ostrand-Rosenberg, Suzanne (Author & Presenter). Cold Spring Harbor Symposium on Tumor Immunology & Immunotherapy. Lecture. "Immune suppression in obesity and tumor progression," Cold Spring Harbor. Suzhou, China. (Oct 22, 2017).

Ostrand-Rosenberg, Suzanne (Author & Presenter). Progress in Vaccination Against Cancer , 17th edition. Keynote/Plenary Address. "The good, the bad, and the in-between: immune suppression, obesity, and tumor progression," PIVAC (Progress in Vaccination Against Cancer). Loutraki, Greece. (Sep 26, 2017).

Ostrand-Rosenberg, Suzanne (Author & Presenter). 47th Annual meeting of the German Society for Immunology. Lecture. "Obesity, immune suppression, & tumor progression," German Society for Immuno9logy. Erlangen, Germany. (Sep 13, 2017).

Ostrand-Rosenberg, Suzanne (Author & Presenter). 22nd Congress of the European Hematology Association. Lecture. "Myeloid-derived suppressor cells (MDSC): Critical cells that link obesity to cancer and drive immune suppression in the tumor microenvironment," European Hematology Association. Madrid, Spain. (Jun 22, 2017).

Ostrand-Rosenberg, Suzanne (Author & Presenter). American Association of Immunologists annual meeting 2017. Keynote/Plenary Address. "The good, the bad, and the in-between: immune suppression, obesity, and tumor progression," American Association of Immunologists. Washington, DC. (May 12, 2017).

Ostrand-Rosenberg, Suzanne (Author & Presenter). II congreso Internacional de Immuno-Oncologia. Keynote/Plenary Address. "Understanding and neutralizing cancer-induced immune suppression to promote antitumor immunity," Mexican National Cancer Institute, Sonora Cancer Research Center, Mexican Society of Medical Oncology. Ciudad Obregon, Sonora, Mexico. (Dec 1, 2016).

Ostrand-Rosenberg, Suzanne (Author & Presenter). Rutgers University. Seminar. "Myeloid-derived Suppressor Cells (MDSC): Bad If You Have Cancer; Good If You’re Pregnant," Rutgers University. Rutgers University. (Oct 28, 2016).

Ostrand-Rosenberg, Suzanne (Author & Presenter). Regulatory Myeloid Suppressor Cells. Lecture. "MDSC: Multi-talented immune suppressive cells that mediate both detrimental & beneficial effects," Wistar Institute. Philadelphia, PA. (Jun 16, 2016).

Ostrand-Rosenberg, Suzanne (Author & Presenter). Immunology, Membrane Dynamics, and Beyond: A Symposium in Honor of Professor Michael Edidin. Lecture. "Immune suppression: bad if you have a tumor, but good if you’re pregnant," Johns Hopkins University. Baltimore, MD. (Jun 6, 2016).

Ostrand-Rosenberg, Suzanne (Author & Presenter). Tumor Immunology Meets Oncology (TIMO). Lecture. "Enhancing antitumor immunity & neutralization of immune suppression in the tumor microenvironment," Martin Luther University, Halle-Wittenberg, Germany. University Hospital Halle. (Apr 29, 2016).

Ostrand-Rosenberg, Suzanne (Author & Presenter). TEDCO. Oral Presentation. "A novel BiTE as an immunotherapy drug for the treatment of cancer," TEDCO. Columbia, MD. (Feb 29, 2016).

Ostrand-Rosenberg, Suzanne (Author & Presenter). IASLC 16th Annual Targeted Therapies of Lung Cancer Conference. Lecture. "Other Immune Suppressive Mechanisms & Their Potential Therapies," International Association for the Study of Lung Cancer. Santa Monica, CA. (Feb 17, 2016).

Ostrand-Rosenberg, Suzanne (Author & Presenter). Joint scientific meeting MedImmune and UMD. Lecture. "A novel recombinant molecule that simultaneously inhibits PDL1/PD1-mediated immune suppression and boosts the activation of tumor-reactive T cells," MedImmune/UMD. Gaithersberg, MD. (Feb 8, 2016).

Ostrand-Rosenberg, Suzanne (Author & Presenter). 3rd Annual Summit on Thoracic Malignancies & Head & Neck Cancers. Lecture. "Novel, non-antibody approaches for blocking the PD-1 immune suppressive pathway and enhancing antitumor immunity," International Association for the study of lung cancer. San Juan, Puerto Rico. (Dec 11, 2015).

Ostrand-Rosenberg, Suzanne. Seminar. "Novel approaches for blocking the PD-1 immune suppressive pathway and enhancing antitumor immunity," University of Rochester. Rochester, NY. (Dec 7, 2015).

Ostrand-Rosenberg, Suzanne (Author & Presenter). Lecture. "Tumor-induced immune suppression: the last obstacle (or just another bump in the road) to global success of cancer immunotherapies?," University of Utah. Salt Lake City, UT. (Aug 19, 2015).

Ostrand-Rosenberg, Suzanne (Author & Presenter). Lecture. "Myeloid cells as an obstacle to cancer immunotherapy," Karolinska Institutet for Cancer Research. Stockholm, Sweden. (Jun 12, 2015).

Ostrand-Rosenberg, Suzanne (Author & Presenter). Cancer Immunotherapy & Immunomonitoring Conference (CITIM). Lecture. "how to survive inf you are a myeloid-derived suppressor cell (MDSC)," CITIM Society. Ljubljana, Slovenia. (Apr 27, 2015).

Ostrand-Rosenberg, Suzanne. Look Ahead Symposium. Keynote/Plenary Address. "The immune system vs. cancer: winners, losers, and complications," UMBC. UMBC. (Apr 15, 2015).

Ostrand-Rosenberg, Suzanne (Author & Presenter). Seminar. "Novel approaches for blocking the PD1 immune suppressive pathway and enhancing antitumor immunity," Wistar Institute. Philadelphia, PA. (Apr 13, 2015).

Ostrand-Rosenberg, Suzanne (Author & Presenter). MedImmune. Lecture. "Novel Strategies for Neutralizing PD-1 Pathway-mediated Immune Suppression in Cancer," MedImmune, Inc.. Gaitherburg, MD. (Dec 18, 2014).

Ostrand-Rosenberg, Suzanne (Author & Presenter). Baylor College of Medicine. Seminar. "Inflammation, Alarmins,and Immune Suppression in the Tumor Microenvironment: It’s the RAGE," Baylor College of Medicine. Dallas, TX. (Oct 21, 2014).

Ostrand-Rosenberg, Suzanne. UMBC President's Council. Oral Presentation. "Activating a Patient’s Immune System to Destroy Cancer Cells," UMBC. United States. (Jul 20, 2014).

Ostrand-Rosenberg, Suzanne (Author & Presenter). Loyola University Cancer Immunotherapy Retreat. Keynote/Plenary Address. "Inflammation and Immune Suppression in the Tumor Microenvironment," Loyola University of Chicago. Loyola University, Chicago. (Jun 3, 2014).

Ostrand-Rosenberg, Suzanne (Author & Presenter). Univ. of Michigan Immunology Seminar Series. Seminar. "Inflammation, Alarmins,and Immune Suppression in the Tumor Microenvironment: It’s the RAGE," Univ. of Michigan, Dept. of Immunology. Ann Arbor, MI. (Apr 2, 2014).

Ostrand-Rosenberg, Suzanne (Author & Presenter). NIH student and post-doc seminar series. Seminar. "Inflammation-induced immune suppression in cancer: It’s the RAGE," NIH. NIH, Bethesda, MD. (Feb 5, 2014).

Ostrand-Rosenberg, Suzanne (Author & Presenter). Midwinter Immunology conference. Lecture. "Inflammation, Alarmins, and Immune Suppression – It’s the RAGE," Midwinter Immunology conference. Asilomar, CA. (Jan 28, 2014).

Ostrand-Rosenberg, Suzanne. Uniformed Services University of the Health Sciences. Lecture. "Inflammation-induced immune suppression in cancer: It’s the RAGE," Uniformed Services University of the Health Sciences. Bethesda, MD. (Nov 22, 2013).

Ostrand-Rosenberg, Suzanne (Author & Presenter), Ostrand-Rosenberg, Suzanne (Coordinator/Organizer). Progress in Vaccination Against Cancer (PIVAC) 15. Lecture. "The continuing saga of understanding & improving anti-tumor immunity: from cancer vaccines to myeloid-derived suppressor cells & PDL1," Progress in Vaccination Against Cancer Society. Tubingen, Germany. (Oct 6, 2013).

Ostrand-Rosenberg, Suzanne. 4th International Symposium on Regulators of Adaptive Immunity. Lecture. "Inflammation-induced immune suppression in cancer: It’s the RAGE," Erlangen University. U. of Erlangen, Germany. (Sep 28, 2013).

Ostrand-Rosenberg, Suzanne. Institute for Human Virology. Lecture. "Inflammation-induced immune suppression in cancer: It’s the RAGE," Institute for Human Virology. Baltimore, MD. (Sep 23, 2013).

Ostrand-Rosenberg, Suzanne. International Congress of Immunology. Lecture. "Tumor-induced Inflammation and Immune Suppression – It’s the RAGE," International Congress of Immunology. Milan, Italy. (Aug 23, 2013).

Ostrand-Rosenberg, Suzanne. Japanese Society of Cancer Immunology Annual meeting. Keynote/Plenary Address. "Inflammation-induced immune suppression in cancer: Myeloid-derived suppressor cells," Japanese Society of Cancer Immunology. Yamaguchi, Japan. (Jul 3, 2013).

Ostrand-Rosenberg, Suzanne. The Association for Cancer Immunotherapy (CIMT) annual conference. Lecture. "Inflammation, alarmins, and immune suppression - It's the RAGE," CIMT. Mainz, Germany. (May 1, 2013).

Ostrand-Rosenberg, Suzanne. Cancer Immunotherapy and Immunomonitoring (CITIM). Keynote/Plenary Address. "Inflammation, alarmins, and immune suppression - It's all about RAGE," CITIM. Krakow, Poland. (Apr 22, 2013).

Ostrand-Rosenberg, Suzanne (Presenter). Progress in vaccination against cancer 12 (PIVAC12). Keynote/Plenary Address. "A tale of two cytokines: inflammation-amplified cross-talk between myeloid cells drives tumor progression.," PIVAC. Nottingham, UK. (Sep 11, 2012).